Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosciens BiopharmaCSCIF 61 Cash-to-Debt is 2.70 as of Jun. 2026, which is 21% below its 10-year median of 3.41. GuruFocus rates CSCIF with a GF Score™ of 61/100 and a GF Value™ of $7.02 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,371 Biotechnology companies, Cosciens Biopharma ranks worse than 62.8% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cosciens Biopharma's cash to debt ratio for the quarter that ended in Jun. 2026 was 2.70.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cosciens Biopharmacould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Cosciens Biopharma's Cash-to-Debt or its related term are showing as below:
CSCIF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.51 Med: 3.41 Max: 16.48
Current: 2.7
During the past 13 years, Cosciens Biopharma's highest Cash to Debt Ratio was 16.48. The lowest was 0.51. And the median was 3.41.
CSCIF's Cash-to-Debt is ranked worse than 62.8% of 1371
companies
in the Biotechnology industry
Industry Median: 6.78
vs CSCIF: 2.70
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Cosciens Biopharma Cash-to-Debt Related Terms
Cosciens Biopharma Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Cosciens Biopharma's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CSCIF vs VRTX, REGN, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, Cosciens Biopharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosciens Biopharma (CSCIF) has a Cash-to-Debt of 2.70 as of Jun. 2026. This is 21% below median its historical median of 3.41. Over the past decade, Cosciens Biopharma's Cash-to-Debt has ranged from 0.51 to 16.48. According to the industry distribution chart, Cosciens Biopharma ranks #861 out of 1371 companies in the Biotechnology industry, placing it in the top 62.8%.
Is Cosciens Biopharma's Cash-to-Debt too high?
Cosciens Biopharma's current Cash-to-Debt of 2.70 is 21% below median its 10-year median of 3.41. Over the past 10 years, this metric has ranged from a low of 0.51 to a high of 16.48. The Biotechnology industry median Cash-to-Debt is 6.78. Cosciens Biopharma's value of 2.70 is 60.2% below this industry median. Based on the distribution chart, Cosciens Biopharma ranks #861 out of 1371 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cosciens Biopharma has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cosciens Biopharma ranks #861 out of 1371 companies for Cash-to-Debt. This places Cosciens Biopharma in the lower half of its industry. The industry median Cash-to-Debt is 6.78. Cosciens Biopharma's value of 2.70 is 60.2% below this benchmark. Historically, Cosciens Biopharma's own Cash-to-Debt has ranged from 0.51 to 16.48 over the past decade. While the company's 10-year median is 3.41 vs. the industry median of 6.78, Cosciens Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.78, based on 1,371 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosciens Biopharma's current Cash-to-Debt of 2.70 is 60.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosciens Biopharma's current Cash-to-Debt is 2.70, which is 21% below median its own 10-year median of 3.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.02, compared to a current price of $5.50 — trading 21.7% below its estimated fair value. The current Cash-to-Debt is 2.70, which is 21% below median its 10-year median of 3.41 and 60.2% below the Biotechnology industry median of 6.78. Cosciens Biopharma's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current Cash-to-Debt is 2.70 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (CSCIF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued.
The current stock price of $5.50 is trading 21.7% below its estimated GF Value™ of $7.02.
GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.
Key valuation signals for CSCIF:
Cash-to-Debt: 2.70 (21% below median its 10-year median of 3.41)
GF Value™: $7.02 vs. price of $5.50 (21.7% below fair value)
Industry Position: 60.2% below the Biotechnology median (#861 of 1371)
No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
61GF Score
Get the complete analysis for CSCIF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSCIF has been successfully added to your 
